ArticleJournal of neurochemistry2026
Sex and Diet Biased Effect of L-DOPA on Iron Accumulation in the Ventral Midbrain.
Article in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reimagining the contribution of iron in Parkinson's disease.Neurobiology of disease · 2026Review
- L-DOPA influences transferrin-dependent iron release at the blood-brain barrier.Fluids and barriers of the CNS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, a region within the ventral midbrain known to accumulate iron. While L-3,4-dihydroxyphenylalanine (L-DOPA) remains the gold standard treatment for PD, its impact on brain iron homeostasis, particularly under varying systemic iron conditions, remains poorly understood. In this study, we investigate how dietary iron status and anti-PD treatments influence brain iron accumulation and regulation in the ventral midbrain, with a focus on sex-specific differences. Male and female Long-Evans rats were placed on iron-adequate (IA), iron-deficient (ID), or iron-repletion (IR) diets from postnatal day (PND) 21 for eight weeks. In the final three weeks, animals received daily subcutaneous injections of L-DOPA, selegiline, or vehicle. Our findings revealed that L-DOPA treatment in IR males significantly increased brain iron levels in the ventral midbrain, whereas females showed no such effect. This sex-specific accumulation was accompanied by the upregulation of iron uptake protein transferrin receptor 1 (TfR1), increased ferroportin (FPN1), and reduced expression of the iron storage protein ferritin heavy chain (FTH1), indicating disrupted iron homeostasis. Furthermore, L-DOPA-treated males on the IR diet exhibited elevated glial fibrillary acidic protein (GFAP) and lipocalin-2 (LCN2), suggesting enhanced oxidative stress and astrocyte activation. Consistent with this, antioxidant enzymes catalase (CAT) and superoxide dismutase 2 (SOD2) were significantly decreased in L-DOPA-treated males on the IR diet, highlighting increased vulnerability to oxidative damage. In contrast, selegiline did not significantly alter brain iron levels or iron-regulatory protein expression, regardless of diet or sex. These findings demonstrate that systemic iron repletion after deficiency sensitizes the male brain to L-DOPA-induced iron accumulation, potentially increasing susceptibility to neurodegeneration. This study highlights the importance of considering that both dietary iron status and biological sex may impact PD treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.